BRNS vs. LYEL, ALEC, IPHA, GLSI, MGNX, GNLX, CKPT, CRGX, VXRT, and ADAP
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Lyell Immunopharma (LYEL), Alector (ALEC), Innate Pharma (IPHA), Greenwich LifeSciences (GLSI), MacroGenics (MGNX), Genelux (GNLX), Checkpoint Therapeutics (CKPT), CARGO Therapeutics (CRGX), Vaxart (VXRT), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry.
Barinthus Biotherapeutics vs.
Lyell Immunopharma (NASDAQ:LYEL) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Lyell Immunopharma had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Lyell Immunopharma and 0 mentions for Barinthus Biotherapeutics. Lyell Immunopharma's average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.
Barinthus Biotherapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Lyell Immunopharma currently has a consensus price target of $1.00, suggesting a potential upside of 42.71%. Barinthus Biotherapeutics has a consensus price target of $5.17, suggesting a potential upside of 416.67%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Lyell Immunopharma.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Barinthus Biotherapeutics' return on equity of -34.26% beat Lyell Immunopharma's return on equity.
Lyell Immunopharma has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.82, indicating that its share price is 182% less volatile than the S&P 500.
Barinthus Biotherapeutics received 1 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
Summary
Barinthus Biotherapeutics beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BRNS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BRNS Stock Alerts